The Claim
Recombinant human TSH activates cyclic AMP signaling in orbital fibroblasts from patients with severe Graves' ophthalmopathy but does not induce significant hyaluronan synthesis in the majority of these cells.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In cells from patients with severe Graves' ophthalmopathy, recombinant human TSH triggers cyclic AMP signaling but does not cause substantial hyaluronan production in most cells.
See the scientific wording
Recombinant human TSH activates cyclic AMP signaling in orbital fibroblasts from patients with severe Graves' ophthalmopathy but fails to induce significant hyaluronan synthesis in the majority of these cells, indicating that TSHR activation alone is insufficient to drive this key pathological feature.
When the TSH receptor on eye fat cells is activated by thyroid-stimulating hormone, it turns on a cAMP signal, but this alone does not make the swelling substance. A different signal, triggered by antibodies found in Graves' disease, turns on a separate pathway that directly increases the production of the swelling substance, which only happens when both the hormone and the antibodies are present.
What the research says
1 studyWhen scientists gave purified TSH to eye fat cells from people with Graves' disease, it turned on a signaling switch (cAMP) but didn't make the swelling substance (hyaluronan). This means TSH by itself can't cause the eye swelling — something else must be needed.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.